India approves Gilead’s remdesivir to treat severe COVID-19 cases

epa08383826 An Indian doctor takes samples from a person during COVID-19 routine testing at a hospital in Bangalore, India, 25 April 2020, during the coronavirus disease (COVID-19) pandemic. Indian Prime Minister Narendra Modi announced on 14 April that the country's initial 21-day lockdown will be extended until 03 May in a bid to quell the widespread of the novel coronavirus. EPA-EFE/JAGADEESH NV

BENGALURU, June 3 (Reuters) - India's government has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients.

Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal clinical trials and is at the forefront of the battle against COVID-19, which has no approved treatment or vaccine.

“(Remdesivir) approved on June 1 under emergency use with condition for five dose administration,” the Drugs Controller General of India said in an email on Tuesday.

Earlier this week, Gilead said the drug showed modest benefit in patients with moderate COVID-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.

“(DCGI) has granted regulatory approval of (remdesivir) for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalised with severe disease,” Gilead said in an email on Wednesday.

The drug was granted emergency use authorization by the U.S. Food and Drug Administration last month and has received approval by Japanese health regulators.

Earlier in the day, South Korea approved the drug’s emergency use and said it will cooperate with Gilead for its swift import.

India’s coronavirus infections crossed 200,000, latest official figures showed, with the death toll at 5,815.

The DCGI decided against extending its use to 10 days, based on existing evidence presented to it at the time of approval, the Indian Express newspaper had reported on Tuesday.

The U.S. drugmaker did not share details on the dosage in its statement.

Gilead had signed non-exclusive licensing pacts last month with five generic drugmakers in India and Pakistan.

“The company anticipates new supply to start to become available in July,” Gilead said.

Governments are racing to bolster supplies of remdesivir, with Europe also vying for the treatment.

(Reporting by Anuron Kumar Mitra and Manas Mishra in Bengaluru; Editing by Louise Heavens and Arun Koyyur)


"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted

[%% img-description %%]

The Spy Bill: An autocratic roadmap to State Capture 2.0

Join Heidi Swart in conversation with Anton Harber and Marianne Merten as they discuss a concerning push to pass a controversial “Spy Bill” into law by May 2024. Tues 5 Dec at 12pm, live, online and free of charge.

A South African Hero: You

There’s a 99.8% chance that this isn’t for you. Only 0.2% of our readers have responded to this call for action.

Those 0.2% of our readers are our hidden heroes, who are fuelling our work and impacting the lives of every South African in doing so. They’re the people who contribute to keep Daily Maverick free for all, including you.

The equation is quite simple: the more members we have, the more reporting and investigations we can do, and the greater the impact on the country.

Be part of that 0.2%. Be a Maverick. Be a Maverick Insider.

Support Daily Maverick→
Payment options